G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-catenin Pathway Suppression

Executive Summary: G007-LK is a nanomolar-potency, highly selective inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), showing robust suppression of Wnt/β-catenin signaling in cellular and in vivo models (APExBIO, B5830). In APC-mutant colorectal cancer and hepatocellular carcinoma (HCC), G007-LK reduces β-catenin levels and tumor growth by inhibiting poly(ADP-ribosyl)ation of TNKS1/2 (Jia et al., 2017). The compound stabilizes AXIN1/2 and angiomotin-like proteins, disrupting β-catenin and YAP activity. G007-LK demonstrates high solubility in DMSO (≥26.5 mg/mL), but is insoluble in water or ethanol, requiring specific handling protocols. Its mechanism and effectiveness are benchmarked across multiple cancer models, supporting its role in dissecting Wnt/β-catenin and Hippo pathways for cancer biology research.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases central to the regulation of Wnt/β-catenin signaling, telomere maintenance, and mitotic processes (Jia et al., 2017). Elevated tankyrase expression is detected in various malignancies, including hepatocellular carcinoma and colorectal cancer. Aberrant Wnt/β-catenin signaling—frequently driven by APC gene mutations—contributes to unchecked cell proliferation and tumorigenesis. Tankyrases modulate AXIN, a key scaffold in the β-catenin destruction complex, through poly(ADP-ribosyl)ation, targeting it for degradation. Inhibition of tankyrase activity leads to AXIN stabilization, β-catenin degradation, and attenuation of oncogenic signaling. Therefore, selective tankyrase inhibitors like G007-LK are critical research tools for probing Wnt pathway function and developing anti-cancer strategies targeting Wnt/β-catenin–dependent tumors.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK (SKU B5830, APExBIO) is a small-molecule inhibitor that binds the catalytic PARP domain of TNKS1 and TNKS2, blocking auto-poly(ADP-ribosyl)ation activity. The compound exhibits IC₅₀ values of 46 nM for TNKS1 and 25 nM for TNKS2 in enzymatic assays (APExBIO). In cellular systems, such as Wnt3a-induced HEK293 cells, G007-LK inhibits Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM. Mechanistically, G007-LK prevents AXIN degradation by tankyrases, leading to increased AXIN1/2, assembly of β-catenin degradasomes, and enhanced proteasomal degradation of cytosolic and nuclear β-catenin. In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK triggers the formation of β-catenin–, β-TrCP–, and ubiquitin–positive degradasomes, reducing Wnt target gene transcription. In hepatocellular carcinoma, G007-LK also stabilizes angiomotin-like proteins (AMOTL1/2), negative regulators of YAP, thus linking tankyrase inhibition to Hippo pathway modulation (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits tankyrase 1 and 2 auto-PARylation in vitro, with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) (APExBIO).
• Suppresses Wnt/β-catenin signaling in Wnt3a-induced HEK293 cells, with ST-Luc reporter IC₅₀ of 0.05 μM (APExBIO).
• Induces AXIN1/2 stabilization and β-catenin degradation in APC-mutant colorectal cancer cells (SW480) (APExBIO).
• Reduces β-catenin and TNKS1/2 levels, while inhibiting tumor growth in COLO-320DM mouse xenograft models (APExBIO).
• Downregulates YAP/TAZ and YAP target gene expression in hepatocellular carcinoma cell lines, accompanied by increased AMOTL1/2 protein abundance (Jia et al., 2017).
• Synergizes with MEK and AKT inhibitors to further suppress HCC cell proliferation (Jia et al., 2017).

This article extends previous overviews (e.g., G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β...) by providing updated benchmarks in both colorectal and liver cancer contexts, with direct comparison of in vitro and in vivo efficacy data. It also clarifies links between Wnt and Hippo pathway modulation, building on workflow-focused summaries (G007-LK: Precision Tankyrase 1/2 Inhibitor for Wnt Signal...).

Applications, Limits & Misconceptions

G007-LK is primarily used in preclinical research to:

• Dissect tankyrase-dependent regulation of Wnt/β-catenin signaling.
• Study β-catenin degradation pathways and AXIN1/2 stabilization in cancer models.
• Investigate Hippo pathway–YAP/TAZ modulation via angiomotin protein stabilization.
• Evaluate anti-tumor efficacy in APC-mutant colorectal and hepatocellular carcinoma models.
• Synergize with MEK/AKT inhibitors to suppress cancer cell proliferation (Jia et al., 2017).

For detailed integration into Wnt pathway workflows and troubleshooting, see G007-LK: Precision Tankyrase 1/2 Inhibitor for Wnt Pathwa..., which this article updates by including recent synergy data and protein-level benchmarks.

Common Pitfalls or Misconceptions

• G007-LK is not active in water or ethanol; DMSO (≥26.5 mg/mL) is required for dissolution (APExBIO).
• It is not a pan-PARP inhibitor; it is highly selective for TNKS1/2 and does not inhibit other PARPs at nanomolar concentrations.
• G007-LK does not directly inhibit β-catenin; activity depends on functional tankyrase/AXIN pathway.
• Long-term storage of G007-LK solutions is discouraged; the compound should be stored as a solid at -20°C (APExBIO).
• Not validated for use as a therapeutic in humans; for research use only.

Workflow Integration & Parameters

For optimal use, dissolve G007-LK in DMSO to a stock concentration of ≥26.5 mg/mL. Warming at 37°C or using an ultrasonic bath aids solubilization. Store solid compound at -20°C and avoid repeated freeze-thaw cycles. In cell-based assays, typical working concentrations range from 10 nM to 1 μM, with efficacy demonstrated in Wnt3a-induced HEK293 and APC-mutant colorectal cancer cells. For in vivo studies, refer to validated dosing regimens in COLO-320DM xenograft models (see the B5830 kit and Jia et al., 2017). G007-LK can be combined with MEK and AKT inhibitors to probe pathway cross-talk and combinatorial anti-tumor effects. For a deeper comparison of workflow strategies, see G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β..., which this article augments with detailed solubility and storage guidance.

Conclusion & Outlook

G007-LK, provided by APExBIO, is a validated, selective tankyrase 1/2 inhibitor enabling precise dissection of Wnt/β-catenin and Hippo signaling in cancer biology. Its nanomolar potency, robust mechanism of action, and reproducible workflow parameters establish it as a benchmark research tool for APC mutation colorectal and hepatocellular carcinoma models. Current evidence supports its utility in elucidating β-catenin degradation, AXIN stabilization, and YAP pathway modulation. G007-LK will continue to facilitate mechanistic studies and preclinical drug development targeting Wnt-driven oncogenesis. For up-to-date protocols and product availability, refer to the G007-LK product page.